Biogen (BIIB) PT Raised to $250 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Rating Summary:
30 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
TD Cowen analyst Phil Nadeau raised the price target on Biogen (NASDAQ: BIIB) to $250.00 (from $225.00) while maintaining a Buy rating.
The analyst comments "We are issuing an updated BIIB model ahead of Q3:26 earnings. We have revised our model to be consistent with BIIB's guidance for Q3:26 and Q4:26 IPR&D. Our Q3:26 and 2026 non-GAAP EPS estimates have changed from $1.90 and $12.40 to $1.99 and $12.30, respectively. Our P.T. has increased from $225 to $250. Please see TD Cowen's Q3 Biotech Earnings Preview for a discussion. Remain Buy."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott Labs (ABT) PT Lowered to $125 at BTIG
- Getty Realty (GTY) Tops Q3 EPS by 5c
- Liberty Oilfield Services (LBRT) Misses Q3 EPS by 1c
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Cowen & Co, Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
